2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…2022 American Transplant Congress
The Impact Of Monoclonal Antibody Against Sars-CoV2 And Vaccination On Outcomes In Kidney Transplant Recipients With Covid-19
NYU Langone Transplant Institute, New York, NY
*Purpose: Solid organ transplant recipients are at high risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) with mortality rates as high as 30%…2022 American Transplant Congress
Basiliximab Provides Similar Efficacy and Renal Recovery in Steroid-Minimal Liver Transplantation
*Purpose: Due to nephrotoxic effects of tacrolimus, previous studies have evaluated the utility of basiliximab to delay or reduce tacrolimus for renal preservation in orthotopic…2022 American Transplant Congress
Improved Mortality in COVID-19 Kidney Transplant Recipients Treated with Bamlanivimab
Nephrology, UC Irvine, Orange, CA
*Purpose: Transplant recipients are particularly vulnerable to catastrophic sequelae of COVID-19. In an early multi-center study of 482 solid organ transplant (SOT) recipients with COVID-19,…2022 American Transplant Congress
Use of Monoclonal Antibodies for Treatment of Solid Organ Transplant Recipients with COVID-19: A Single Center Experience
*Purpose: The risk of severe COVID-19 requiring hospitalization and death is higher in solid organ transplant recipients (SOTr). There remains limited data on the use…2022 American Transplant Congress
Daratumumab for Recurrence of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits in a Post-Kidney Transplant Recipient: A Case Report
*Purpose: Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits (PGNMID) is a rare kidney disease associated with a high rate of recurrence post-kidney transplantation resulting in graft…2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…2022 American Transplant Congress
The Addition of Bortezomib to a Rituximab Based Antibody Mediated Rejection Treatment Protocol in Lung Transplant
Loyola University Medical Center, Maywood, IL
*Purpose: To evaluate the impact of antibody mediated rejection (AMR) treatment with rituximab combined with bortezomib vs. rituximab alone on patient survival, graft survival, and…2022 American Transplant Congress
Use of Monoclonal Antibody Casirivimab-Imdevimab for Treatment of COVID-19 in Kidney Transplant Recipients
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Kidney transplant recipients are at high-risk for severe coronavirus disease 2019 (COVID-19). Studies suggest that intervention with monoclonal antibody (MAB) treatment may decrease hospitalization…2021 American Transplant Congress
Pharmacokinetic and Toxicity Studies of an Anti CD40L Antibody, At-1501 in Rhesus Macaques
1Novus Therapeutics, Irvine, CA, 2ALS Therapy Development Institute, Cambridge, MA
*Purpose: CD40L is a costimulatory receptor for CD40 found on T helper cells. Binding of CD40L on T cells to CD40 on antigen presenting cells…
- 1
- 2
- 3
- …
- 5
- Next Page »